U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Elevated circulating parathyroid hormone level

MedGen UID:
167805
Concept ID:
C0857973
Finding
Synonyms: Elevated serum parathyroid hormone; Elevated serum PTH; Increased serum parathyroid hormone
 
HPO: HP:0003165

Definition

An abnormal increased concentration of parathyroid hormone. [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVElevated circulating parathyroid hormone level

Conditions with this feature

Primary hypomagnesemia
MedGen UID:
120640
Concept ID:
C0268448
Disease or Syndrome
Familial hypomagnesemia with hypercalciuria and nephrocalcinosis is a progressive renal disorder characterized by excessive urinary Ca(2+) and Mg(2+) excretion. There is progressive loss of kidney function, and in about 50% of cases, the need for renal replacement therapy arises as early as the second decade of life (summary by Muller et al., 2006). Amelogenesis imperfecta may also be present in some patients (Bardet et al., 2016). A similar disorder with renal magnesium wasting, renal failure, and nephrocalcinosis (HOMG5; 248190) is caused by mutations in another tight-junction gene, CLDN19 (610036), and is distinguished by the association of severe ocular involvement. For a discussion of phenotypic and genetic heterogeneity of familial hypomagnesemia, see HOMG1 (602014).
Vitamin D-dependent rickets, type 1
MedGen UID:
124344
Concept ID:
C0268689
Disease or Syndrome
Vitamin D-dependent rickets is a disorder of bone development that leads to softening and weakening of the bones (rickets). There are several forms of the condition that are distinguished primarily by their genetic causes: type 1A (VDDR1A), type 1B (VDDR1B), and type 2A (VDDR2A). There is also evidence of a very rare form of the condition, called type 2B (VDDR2B), although not much is known about this form.\n\nThe signs and symptoms of vitamin D-dependent rickets begin within months after birth, and most are the same for all types of the condition. The weak bones often cause bone pain and delayed growth and have a tendency to fracture. When affected children begin to walk, they may develop abnormally curved (bowed) legs because the bones are too weak to bear weight. Impaired bone development also results in widening of the areas near the ends of bones where new bone forms (metaphyses), especially in the knees, wrists, and ribs. Some people with vitamin D-dependent rickets have dental abnormalities such as thin tooth enamel and frequent cavities. Poor muscle tone (hypotonia) and muscle weakness are also common in this condition, and some affected individuals develop seizures.\n\nIn vitamin D-dependent rickets, there is an imbalance of certain substances in the blood. An early sign in all types of the condition is low levels of the mineral calcium (hypocalcemia), which is essential for the normal formation of bones and teeth. Affected individuals also develop high levels of a hormone involved in regulating calcium levels called parathyroid hormone (PTH), which leads to a condition called secondary hyperparathyroidism. Low levels of a mineral called phosphate (hypophosphatemia) also occur in affected individuals. Vitamin D-dependent rickets types 1 and 2 can be grouped by blood levels of a hormone called calcitriol, which is the active form of vitamin D; individuals with VDDR1A and VDDR1B have abnormally low levels of calcitriol and individuals with VDDR2A and VDDR2B have abnormally high levels.\n\nHair loss (alopecia) can occur in VDDR2A, although not everyone with this form of the condition has alopecia. Affected individuals can have sparse or patchy hair or no hair at all on their heads. Some affected individuals are missing body hair as well.
Vitamin D-dependent rickets type II with alopecia
MedGen UID:
90989
Concept ID:
C0342646
Disease or Syndrome
Vitamin D-dependent rickets type 2A (VDDR2A) is caused by a defect in the vitamin D receptor gene. This defect leads to an increase in the circulating ligand, 1,25-dihydroxyvitamin D3. Most patients have total alopecia in addition to rickets. VDDR2B (600785) is a form of vitamin D-dependent rickets with a phenotype similar to VDDR2A but a normal vitamin D receptor, in which end-organ resistance to vitamin D has been shown to be caused by a nuclear ribonucleoprotein that interferes with the vitamin D receptor-DNA interaction. For a general phenotypic description and a discussion of genetic heterogeneity of rickets due to disorders in vitamin D metabolism or action, see vitamin D-dependent rickets type 1A (VDDR1A; 264700).
Familial X-linked hypophosphatemic vitamin D refractory rickets
MedGen UID:
196551
Concept ID:
C0733682
Disease or Syndrome
The phenotypic spectrum of X-linked hypophosphatemia (XLH) ranges from isolated hypophosphatemia to severe lower-extremity bowing. XLH frequently manifests in the first two years of life when lower-extremity bowing becomes evident with the onset of weight bearing; however, it sometimes is not manifest until adulthood, as previously unevaluated short stature. In adults, enthesopathy (calcification of the tendons, ligaments, and joint capsules) associated with joint pain and impaired mobility may be the initial presenting complaint. Persons with XLH are prone to spontaneous dental abscesses; sensorineural hearing loss has also been reported.
Neonatal severe primary hyperparathyroidism
MedGen UID:
331326
Concept ID:
C1832615
Disease or Syndrome
Neonatal severe hyperparathyroidism usually manifests in the first 6 months of life with severe hypercalcemia, bone demineralization, and failure to thrive. Early diagnosis is critical because untreated NSHPT can be a devastating neurodevelopmental disorder, which in some cases is lethal without parathyroidectomy. Some infants have milder hyperparathyroidism and a substantially milder clinical presentation and natural history (summary by Egbuna and Brown, 2008).
Pseudohypoparathyroidism type 1B
MedGen UID:
350343
Concept ID:
C1864100
Disease or Syndrome
Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.
Craniodiaphyseal dysplasia, autosomal dominant
MedGen UID:
382678
Concept ID:
C2675746
Disease or Syndrome
Craniodiaphyseal dysplasia (CDD) is a severe bone dysplasia characterized by massive generalized hyperostosis and sclerosis, especially involving the skull and facial bones. Progressive bony encroachment upon cranial foramina leads to severe neurologic impairment in childhood (summary by Brueton and Winter, 1990). The sclerosis is so severe that the resulting facial distortion is referred to as 'leontiasis ossea' (leonine facies), and the bone deposition results in progressive stenosis of craniofacial foramina (summary by Kim et al., 2011).
Hypophosphatemic rickets and hyperparathyroidism
MedGen UID:
383131
Concept ID:
C2677524
Disease or Syndrome
Vitamin D-dependent rickets, type 2B
MedGen UID:
411667
Concept ID:
C2748783
Disease or Syndrome
Vitamin D-dependent rickets type 2B with normal vitamin D receptor (VDDR2B) is an unusual form of rickets due to abnormal expression of a hormone response element-binding protein that interferes with the normal function of the vitamin D receptor. Vitamin D-dependent rickets type 2A (VDDR2A) is caused by mutation in the vitamin D receptor gene (VDR; 601769), and most patients have alopecia in addition to rickets. For a general phenotypic description and a discussion of genetic heterogeneity of rickets due to disorders in vitamin D metabolism or action, see vitamin D-dependent rickets type 1A (VDDR1A; 264700).
Pseudohypoparathyroidism type 1C
MedGen UID:
420958
Concept ID:
C2932716
Disease or Syndrome
Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.
Pseudohypoparathyroidism type II
MedGen UID:
444371
Concept ID:
C2932717
Disease or Syndrome
Pseudohypoparathyroidism (PHP) is a term applied to a heterogeneous group of disorders whose common feature is resistance to parathyroid hormone (PTH; 168450). PHP type II is characterized by a normal cAMP response to PTH infusion, but a deficient phosphaturic response, indicating a defect distal to cAMP generation in renal cells. The clinical features of Albright hereditary osteodystrophy (AHO; see 103580) are not present in PHP II (Mantovani and Spada, 2006). For a general phenotypic description, classification, and a discussion of molecular genetics of pseudohypoparathyroidism, see PHP1A (103580).
Fanconi renotubular syndrome 2
MedGen UID:
462002
Concept ID:
C3150652
Disease or Syndrome
Any Fanconi syndrome in which the cause of the disease is a mutation in the SLC34A1 gene.
Acrodysostosis 1 with or without hormone resistance
MedGen UID:
477858
Concept ID:
C3276228
Disease or Syndrome
Acrodysostosis-1 (ACRDYS1) is a form of skeletal dysplasia characterized by short stature, severe brachydactyly, facial dysostosis, and nasal hypoplasia. Affected individuals often have advanced bone age and obesity. Laboratory studies show resistance to multiple hormones, including parathyroid, thyrotropin, calcitonin, growth hormone-releasing hormone, and gonadotropin (summary by Linglart et al., 2011). However, not all patients show endocrine abnormalities (Lee et al., 2012). Genetic Heterogeneity of Acrodysostosis See also ACRDYS2 (614613), caused by mutation in the PDE4D gene (600129) on chromosome 5q12.
Pseudohypoparathyroidism type I A
MedGen UID:
488447
Concept ID:
C3494506
Disease or Syndrome
Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.
Spondyloepiphyseal dysplasia, nishimura type
MedGen UID:
930816
Concept ID:
C4305147
Disease or Syndrome
The Nishimura type of spondyloepiphyseal dysplasia (SEDN) is characterized by disproportionate short stature with short limbs, small hands and feet, and midface hypoplasia with small nose. Radiologic hallmarks include mild spondylar dysplasia, delayed epiphyseal ossification of the hip and knee, and severe brachydactyly with cone-shaped phalangeal epiphyses (Grigelioniene et al., 2019).
Hyperuricemic nephropathy, familial juvenile type 4
MedGen UID:
934708
Concept ID:
C4310741
Disease or Syndrome
Autosomal dominant tubulointerstitial kidney disease-5 (ADTKD5) is characterized by the onset of progressive chronic renal disease in the first decades of life. Mild hyperuricemia may be present, but gout, hypertension, and proteinuria are usually absent. The disease may be associated with anemia or neutropenia. Some patients may have additional findings, including poor overall growth and impaired cognitive function. Renal biopsy shows tubulointerstitial abnormalities with atrophic tubules and fibrosis; secondary glomerular abnormalities and simple cysts may also be present (summary by Bolar et al., 2016). For a discussion of genetic heterogeneity and revised nomenclature of ADTKD, see ADTKD1 (162000).
Familial juvenile hyperuricemic nephropathy type 1
MedGen UID:
1645893
Concept ID:
C4551496
Disease or Syndrome
Autosomal dominant tubulointerstitial kidney disease – UMOD (ADTKD-UMOD) is characterized by normal urinalysis and slowly progressive chronic kidney disease (CKD), usually first noted in the teen years and progressing to end-stage renal disease (ESRD) between the third and seventh decades. Hyperuricemia is often present from an early age, and gout (resulting from reduced kidney excretion of uric acid) occurs in the teenage years in about 8% of affected individuals and develops in 55% of affected individuals over time.
Tumoral calcinosis, hyperphosphatemic, familial, 3
MedGen UID:
1638917
Concept ID:
C4693864
Disease or Syndrome
Hyperphosphatemic familial tumoral calcinosis (HFTC) is a rare autosomal recessive metabolic disorder characterized by the progressive deposition of basic calcium phosphate crystals in periarticular spaces, soft tissues, and sometimes bone (Chefetz et al., 2005). The biochemical hallmark of tumoral calcinosis is hyperphosphatemia caused by increased renal absorption of phosphate due to loss-of-function mutations in the FGF23 (605380) or GALNT3 (601756) gene. The term 'hyperostosis-hyperphosphatemia syndrome' (HHS) is sometimes used when the disorder is characterized by involvement of the long bones associated with the radiographic findings of periosteal reaction and cortical hyperostosis. Although some have distinguished HHS from FTC by the presence of bone involvement and the absence of skin involvement (Frishberg et al., 2005), Ichikawa et al. (2010) concluded that the 2 entities represent a continuous spectrum of the same disease, best described as familial hyperphosphatemic tumoral calcinosis. HFTC is considered to be the clinical converse of autosomal dominant hypophosphatemic rickets (ADHR; 193100), an allelic disorder caused by gain-of-function mutations in the FGF23 gene and associated with hypophosphatemia and decreased renal phosphate absorption (Chefetz et al., 2005; Ichikawa et al., 2005). For a general phenotypic description and a discussion of genetic heterogeneity of HFTC, see 211900.
Vitamin D-dependent rickets, type 3
MedGen UID:
1725534
Concept ID:
C5436733
Disease or Syndrome
Vitamin D-dependent rickets-3 (VDDR3) is characterized by early-onset rickets, reduced serum levels of the vitamin D metabolites 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and deficient responsiveness to the parent molecule as well as activated forms of vitamin D (Roizen et al., 2018). For discussion of genetic heterogeneity of vitamin D-dependent rickets, see 264700.

Professional guidelines

PubMed

Brandi L
Dan Med Bull 2008 Nov;55(4):186-210. PMID: 19232159
Irvin GL 3rd, Sfakianakis G, Yeung L, Deriso GT, Fishman LM, Molinari AS, Foss JN
Arch Surg 1996 Oct;131(10):1074-8. doi: 10.1001/archsurg.1996.01430220068015. PMID: 8857905
Rizzoli R, Vadas L, Bonjour JP
Nucl Med Biol 1994 Apr;21(3):337-47. doi: 10.1016/0969-8051(94)90057-4. PMID: 9234299

Recent clinical studies

Etiology

Zambrano A, Tintut Y, Demer LL, Hsu JJ
Heart 2023 Jul 12;109(15):1139-1145. doi: 10.1136/heartjnl-2022-321986. PMID: 36702539Free PMC Article
Anderson LJ, Lee J, Anderson B, Lee B, Migula D, Sauer A, Chong N, Liu H, Wu PC, Dash A, Li YP, Garcia JM
J Cachexia Sarcopenia Muscle 2022 Apr;13(2):1124-1133. Epub 2022 Jan 28 doi: 10.1002/jcsm.12918. PMID: 35088949Free PMC Article
Winters SJ
J Clin Endocrinol Metab 2021 Sep 27;106(10):2819-2827. doi: 10.1210/clinem/dgab430. PMID: 34125228
Ramos Ruiz P, Jaulent Huertas L, Castañeda Sancirilo M, Martínez Díaz JJ, Clavel Ruipérez G, García de Guadiana Romualdo L, Wasniewski S, Merelo Nicolás M, García Escribano I, Soria Arcos F, Castillo Moreno JA, Consuegra Sánchez L
Med Intensiva (Engl Ed) 2018 Mar;42(2):73-81. Epub 2017 Nov 8 doi: 10.1016/j.medin.2017.09.011. PMID: 29128315
Zittermann A, Ernst JB
Nutr Metab Cardiovasc Dis 2016 Nov;26(11):971-979. Epub 2016 Jun 28 doi: 10.1016/j.numecd.2016.06.007. PMID: 27493144

Diagnosis

Hawkes CP, Al Jubeh JM, Li D, Tucker SE, Rajiyah T, Levine MA
J Clin Endocrinol Metab 2022 May 17;107(6):e2449-e2458. doi: 10.1210/clinem/dgac086. PMID: 35165722Free PMC Article
Zittermann A, Ernst JB
Nutr Metab Cardiovasc Dis 2016 Nov;26(11):971-979. Epub 2016 Jun 28 doi: 10.1016/j.numecd.2016.06.007. PMID: 27493144
Barman Balfour JA, Scott LJ
Drugs 2005;65(2):271-81. doi: 10.2165/00003495-200565020-00007. PMID: 15631545
Rizzoli R, Vadas L, Bonjour JP
Nucl Med Biol 1994 Apr;21(3):337-47. doi: 10.1016/0969-8051(94)90057-4. PMID: 9234299
Emmertsen K
Dan Med Bull 1985 Mar;32(1):1-28. PMID: 2859145

Therapy

Slouma M, Sahli H, Bahlous A, Laadhar L, Smaoui W, Rekik S, Gharsallah I, Sallami M, Moussa FB, Elleuch M, Cheour E
Adv Rheumatol 2020 Feb 26;60(1):15. doi: 10.1186/s42358-020-0118-0. PMID: 32102689
Zittermann A, Ernst JB
Nutr Metab Cardiovasc Dis 2016 Nov;26(11):971-979. Epub 2016 Jun 28 doi: 10.1016/j.numecd.2016.06.007. PMID: 27493144
Dusso A, González EA, Martin KJ
Best Pract Res Clin Endocrinol Metab 2011 Aug;25(4):647-55. doi: 10.1016/j.beem.2011.05.005. PMID: 21872805
Barman Balfour JA, Scott LJ
Drugs 2005;65(2):271-81. doi: 10.2165/00003495-200565020-00007. PMID: 15631545
Nemeth EF
Curr Pharm Des 2002;8(23):2077-87. doi: 10.2174/1381612023393387. PMID: 12171519

Prognosis

Anderson LJ, Lee J, Anderson B, Lee B, Migula D, Sauer A, Chong N, Liu H, Wu PC, Dash A, Li YP, Garcia JM
J Cachexia Sarcopenia Muscle 2022 Apr;13(2):1124-1133. Epub 2022 Jan 28 doi: 10.1002/jcsm.12918. PMID: 35088949Free PMC Article
Wajda J, Świat M, Owczarek AJ, Holecki M, Duława J, Brzozowska A, Olszanecka-Glinianowicz M, Chudek J
J Stroke Cerebrovasc Dis 2019 May;28(5):1160-1167. Epub 2019 Jan 16 doi: 10.1016/j.jstrokecerebrovasdis.2019.01.006. PMID: 30658955
Ramos Ruiz P, Jaulent Huertas L, Castañeda Sancirilo M, Martínez Díaz JJ, Clavel Ruipérez G, García de Guadiana Romualdo L, Wasniewski S, Merelo Nicolás M, García Escribano I, Soria Arcos F, Castillo Moreno JA, Consuegra Sánchez L
Med Intensiva (Engl Ed) 2018 Mar;42(2):73-81. Epub 2017 Nov 8 doi: 10.1016/j.medin.2017.09.011. PMID: 29128315
Komaba H, Fukagawa M
Nefrologia 2009;29(5):392-6. doi: 10.3265/Nefrologia.2009.29.5.5400.en.full. PMID: 19820750
Emmertsen K
Dan Med Bull 1985 Mar;32(1):1-28. PMID: 2859145

Clinical prediction guides

Anderson LJ, Lee J, Anderson B, Lee B, Migula D, Sauer A, Chong N, Liu H, Wu PC, Dash A, Li YP, Garcia JM
J Cachexia Sarcopenia Muscle 2022 Apr;13(2):1124-1133. Epub 2022 Jan 28 doi: 10.1002/jcsm.12918. PMID: 35088949Free PMC Article
Slouma M, Sahli H, Bahlous A, Laadhar L, Smaoui W, Rekik S, Gharsallah I, Sallami M, Moussa FB, Elleuch M, Cheour E
Adv Rheumatol 2020 Feb 26;60(1):15. doi: 10.1186/s42358-020-0118-0. PMID: 32102689
Ramos Ruiz P, Jaulent Huertas L, Castañeda Sancirilo M, Martínez Díaz JJ, Clavel Ruipérez G, García de Guadiana Romualdo L, Wasniewski S, Merelo Nicolás M, García Escribano I, Soria Arcos F, Castillo Moreno JA, Consuegra Sánchez L
Med Intensiva (Engl Ed) 2018 Mar;42(2):73-81. Epub 2017 Nov 8 doi: 10.1016/j.medin.2017.09.011. PMID: 29128315
Imanishi Y, Kobayashi K, Kawata T, Inaba M, Nishizawa Y
Ther Apher Dial 2007 Oct;11 Suppl 1:S32-7. doi: 10.1111/j.1744-9987.2007.00519.x. PMID: 17976083
Kestenbaum B, Belozeroff V
Eur J Clin Invest 2007 Aug;37(8):607-22. doi: 10.1111/j.1365-2362.2007.01840.x. PMID: 17635571

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...